ATE448234T1 - Olanzapin-analoga und verfahren zu ihrer verwendung - Google Patents

Olanzapin-analoga und verfahren zu ihrer verwendung

Info

Publication number
ATE448234T1
ATE448234T1 AT06801404T AT06801404T ATE448234T1 AT E448234 T1 ATE448234 T1 AT E448234T1 AT 06801404 T AT06801404 T AT 06801404T AT 06801404 T AT06801404 T AT 06801404T AT E448234 T1 ATE448234 T1 AT E448234T1
Authority
AT
Austria
Prior art keywords
methods
olnzapine
analogues
relates
novel compounds
Prior art date
Application number
AT06801404T
Other languages
German (de)
English (en)
Inventor
James White
Kazumi Shiosaki
David Hangauer
Michael Solomon
Dale Edgar
Original Assignee
Hypnion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypnion Inc filed Critical Hypnion Inc
Application granted granted Critical
Publication of ATE448234T1 publication Critical patent/ATE448234T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT06801404T 2005-08-11 2006-08-11 Olanzapin-analoga und verfahren zu ihrer verwendung ATE448234T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70736805P 2005-08-11 2005-08-11
US11/502,789 US7807828B2 (en) 2005-08-11 2006-08-10 Olanzapine analogs and methods of use thereof
PCT/US2006/031602 WO2007022068A1 (en) 2005-08-11 2006-08-11 Olanzapine analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE448234T1 true ATE448234T1 (de) 2009-11-15

Family

ID=37460090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06801404T ATE448234T1 (de) 2005-08-11 2006-08-11 Olanzapin-analoga und verfahren zu ihrer verwendung

Country Status (8)

Country Link
US (1) US7807828B2 (enExample)
EP (1) EP1915379B1 (enExample)
JP (1) JP2009504676A (enExample)
AT (1) ATE448234T1 (enExample)
CA (1) CA2617107C (enExample)
DE (1) DE602006010400D1 (enExample)
ES (1) ES2333983T3 (enExample)
WO (1) WO2007022068A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
WO2007092333A1 (en) * 2006-02-03 2007-08-16 Hypnion, Inc. Use of olopatadine for treating sleep disorders
WO2008050341A2 (en) * 2006-10-25 2008-05-02 Ramot At Tel-Aviv University Ltd Novel psychotropic agents having glutamate nmda activity
JP2011506441A (ja) * 2007-12-12 2011-03-03 アムジエン・インコーポレーテツド グリシン輸送体−１阻害薬
AR084867A1 (es) * 2011-02-07 2013-07-10 Lilly Co Eli Compuestos de acido [(5h-pirrolo[2,1-c][1,4]benzodiazepin-11-il)piperazin-1-il]-2,2-dimetilpropanoico sustituido como antagonistas de 5-ht/agonistas inversos de actividad dual
PL395468A1 (pl) 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Zwiazki amidoalkilopiperazynylowe do leczenia chorób osrodkowego ukladu nerwowego
DK2729474T3 (en) 2011-07-08 2018-05-22 Lilly Co Eli (THIENO [2,3-b] [1,5] BENZOXAZEPIN-4-YL) PIPERAZIN-1-YL COMPOUNDS AS H1-INVERSE AGONISTS / 5-HT2A DOUBLE EFFECTS
AU2012300451B2 (en) * 2011-08-30 2016-10-13 Eli Lilly And Company (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity H1 inverse agonists/5-HT 2A antagonists
PL2943498T3 (pl) 2013-01-14 2018-01-31 Lilly Co Eli Związki (tieno[2,3-b][1,5]benzoksazepin-4-ylo)piperazyn-1-ylowe jako odwrotni agoniści h1 / antagoniści 5-ht2a o podwójnej aktywności
TW201625644A (zh) 2014-04-29 2016-07-16 美國禮來大藥廠 作為選擇性５－ＨＴＡ反向促效劑之（噻吩并［２，３－ｂ］［１，５］苯并氧氮呯－４－基）哌嗪－１－基化合物
AU2019205329B2 (en) * 2018-01-05 2023-04-20 Impel Pharmaceuticals Inc. Intranasal delivery of olanzapine by precision olfactory device
AU2020370063B2 (en) * 2019-10-21 2025-10-23 Alairion, Inc. 3-(4-(11H-dibenzo[b,e][1,4]azepin-6-yl)piperazin-1-yl)- and 3-(4-(dibenzo[b,f][1,4]oxazepin/thiazepin/diazepin-11-yl)piperazin-1-yl)-propanoic acid derivatives as H1 and 5-HT2A-receptor modulators for the treatment of sleep disorders
CN114685527B (zh) * 2020-12-25 2024-03-05 长沙博源医疗科技有限公司 一种奥氮平衍生物、免疫原、抗奥氮平特异性抗体及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
US5602124A (en) 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
US5744470A (en) * 1996-03-11 1998-04-28 Eli Lilly And Company Method for treating insomnia
US6271225B1 (en) 1997-09-02 2001-08-07 Welfide Corporation Fused thiophene compounds and medicinal use thereof
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
JP2005529840A (ja) * 2001-10-16 2005-10-06 ヒプニオン， インコーポレイテッド Ｃｎｓ標的モジュレータを使用するｃｎｓ障害の治療
JP2007505106A (ja) 2003-09-09 2007-03-08 イーライ リリー アンド カンパニー アゼピン、オキサゼピン、およびチアゼピンの置換ピペラジン

Also Published As

Publication number Publication date
DE602006010400D1 (de) 2009-12-24
US20070043021A1 (en) 2007-02-22
JP2009504676A (ja) 2009-02-05
CA2617107C (en) 2014-07-08
EP1915379A1 (en) 2008-04-30
US7807828B2 (en) 2010-10-05
ES2333983T3 (es) 2010-03-03
WO2007022068A1 (en) 2007-02-22
EP1915379B1 (en) 2009-11-11
CA2617107A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
NO20071127L (no) Triazoloftalaziner
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
ATE420557T1 (de) Verwendung von sulfonylharnstoffen
DK1778236T3 (da) Modificerede pyrimidin-glucocorticoid-receptor-modulatorer
ATE456276T1 (de) Verwendung dekrementeller zuweisungen
ATE477249T1 (de) Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes
TW200640924A (en) VEGF-R2 inhibitors and methods
ATE543910T1 (de) Verfahren und materialien zur herstellung von simvastatin und verwandten verbindungen
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
WO2006049734A3 (en) Quetiapine analogs and methods of use thereof
DE602006004463D1 (de) Kristallform von asenapinmaleat
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
ATE512141T1 (de) Verwendung von tetrahydrobenzoxazinen als antioxidantien
ATE540755T1 (de) Verwendung von katalysatorzusammensetzungen und verfahren zur oxychlorierung
EP2089021A4 (en) USE OF CARBOXYAMIDOTRIAZOLE OROTATE (CAI) IN MACULAR DEGENERATION
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE439831T1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
DE502007003652D1 (de) Verwendung von nitratsalzen zur unterdrückung störender gerüche
DE602006009513D1 (de) Verwendung von phenylsemicarbazonen für die saatgutbeizung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties